Results 41 to 50 of about 81,297 (236)

Switching Therapy to the Second Brand of Generic Atorvastatin: A 6-Month Retrospective Cohort, Real-World Study

Drugs - Real World Outcomes
Introduction High levels of low-density lipoprotein-cholesterol (LDL) is a major risk factor for cardiovascular diseases. While treatment with atorvastatin is beneficial, the original atorvastatin may be cost prohibitive to some patients.
Panisa Manasirisuk, Somsak Tiamkao, Chaiyasith Wongvipaporn, Nanthaphan Chainirun, Kittisak Sawanyawisuth   +4 more
doaj   +1 more source

Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling

Advanced Healthcare Materials, EarlyView.
Emerging advances in three‐dimensional bioprinting and computational modeling are reshaping cardiovascular (CV) research by enabling more realistic, patient‐specific tissue platforms. This review surveys cutting‐edge approaches that merge biomimetic CV constructs with computational simulations to overcome the limitations of traditional models, improve ...
Tanmay Mukherjee, Mehdi Salar Amoli, Sarah Rezapourdamanab, Lama Rita El Shammas, Martin L. Tomov, Emilio A. Mendiola, Vahid Serpooshan, Reza Avazmohammadi   +7 more
wiley   +1 more source

Statin therapy in critical illness : an international survey of intensive care physicians' opinions, attitudes and practice [PDF]

, 2012
Background Pleotropic effects of statins on inflammation are hypothesised to attenuate the severity of and possibly prevent the occurrence of the host inflammatory response to pathogen and infection-related acute organ failure.
Di Gangi, Stefania, Kruger, Peter S., McAuley, Danny F., Perkins, Gavin D., Scales, Damon C., Shankar-Hari, Manu, Terblanche, Marius   +6 more
core   +1 more source

Preliminary Study of a Ninj1‐Loaded Bimodal Ultrasound/NIR Fluorescence Targeted Molecular Probe for Diagnosing Early‐Stage Inflammation in Coronary Microvascular Dysfunction

Advanced Healthcare Materials, EarlyView.
Coronary microvascular dysfunction (CMD) targeting remains a challenge for precise diagnosis. This work presents a dual‐modal nanoprobe (T‐IR780‐NBs) that combines ultrasound contrast with near‐infrared fluorescence. This technology utilizes proteomics‐derived antibodies that specifically localize to inflamed and injured cardiac tissue, enabling ...
Xiaohui Xu, Lina Guan, Baihetiya Tayier, Chen Yuan, Shangke Chen, Qi Shi, Yuming Mu   +6 more
wiley   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3

Advanced Science, EarlyView.
In MASLD, YTHDC1 undergoes increased lactylation and ubiquitination, reducing its expression. AARS1 mediates lactylation at lysine 565, while disrupted binding to LDHA further promotes lactylation, suppressing YTHDC1. This downregulation enhances PTPN22 mRNA stability, leading to NLRP3 dephosphorylation and activation, which exacerbates inflammation ...
Feng Zhang, Linghua Zeng, Kunkun Zou, Keying Lin, Fangting Yao, Jinglun Song, Shumeng Zhang, Hanshu Feng, Zhichao Yang, Chunlei Wang, Hongtao Diao, Xue Kong, Tengfei Pan, Joonki Kim, Tianqi Duo, Linqiang Li, Yu Bian   +16 more
wiley   +1 more source

Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity

Journal of Lipid Research, 1998
The effects of atorvastatin on the expression of the hepatic HMG-CoA reductase and LDL receptor genes were investigated in rats. Like the other statins, atorvastatin increased the rate of degradation and presumably cycling of the hepatic LDL receptor. In
Gene C. Ness, Christopher M. Chambers, Dayami Lopez   +2 more
doaj   +1 more source

Redemptive benefit of atorvastatin in the risk factors of coronary artery disease [PDF]

, 2011
Cardiovascular disease, in particular coronary artery disease (CAD), is the principal cause of mortality in developed countries. The classical acute phase protein, C-reactive protein (CRP) is an exquisitely sensitive systemic marker of disease ...
Jayaraman Gowri , Arumugam Vijaya Anand , Shanmugam Achiraman , Govindha Raj Archunan , Subramaniyam Kalavathy , Palanisamy Sampath Kumar , Kalaiyarasan Vijaya Kumar Int J Cur Biomed Phar Res.
core  

Az atorvastatin/amlodipin fix kombináció versus az atorvastatinterápia a terápiahűség tükrében [PDF]

, 2016
Absztrakt Bevezetés: A hypertonia és a dyslipidaemia módosítható cardiovascularis kockázati tényezők. Hazánkban a hypertonia és a dyslipidaemia egyaránt népbetegségnek számítanak.
Ferenci, Tamás, Simonyi, Gábor
core   +1 more source

Amyloid β Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease

Advanced Science, EarlyView.
This research identified cardiac amyloid pathology, neurotrophic factor depletion, and reduced myocardial nerve function in a transgenic model of cerebral amyloidosis (Tg2576), Aβ‐challenged cardiomyocytes, and in human AD heart tissue. These findings carry significant diagnostic and therapeutic implications, emphasizing the role of neuro‐signaling ...
Andrea Elia, Rebecca Parodi‐Rullan, Rafael Vazquez‐Torres, Ashley Carey, Huaqing Zhao, Sabzali Javadov, Silvia Fossati   +6 more
wiley   +1 more source